A summary of Blood Cancer Awareness Month at the Oxford Cancer Centre
As part of the 110th Anniversary celebrations for the founding of Sichuan University (SCU), members of the Sichuan University (West China Hospital)-Oxford University Gastrointestinal Cancer Centre attended the first Centre Forum on Gastrointestinal Cancer at SCU. In attendance was an internationally known faculty of researchers who explored basic, translational and clinical aspects of colorectal, oesophageal and gastric cancer in a series of plenary lectures. See the full event agenda here.
The event built on the expertise of leading faculty members from Sichuan and Oxford University, complemented by international experts who are recognized leaders in their respective fields.
The lectures provided state of art updates on clinical management and insights into the biology of these tumour types and how this information can be exploited to identify new disease markers and therapeutic targets.
The forum attracted over 5,000 clinicians virtually from across China, representing all of the specialties involved in the management of GI cancer and basic scientists with an interest in translational and precision cancer medicine and is considered a great success.
Many thanks to the superb technical team who assured that all zoom delivered lectures were delivered with perfect clarity.
It gives the Centre great pleasure to announce that they will hold the second Huaxi SCU-Oxford Forum on Gastrointestinal Cancer in Queens College Oxford in early September 2021, in partnership with collaborators from the University of Oslo, with whom they have formed the Colorectal Cancer Network.
The Roy and Milne labs are investigating the developmental origins of infant leukaemia and its influence on the biology of the disease
Prof Paresh Vyas and team have been investigating how a better understanding of clonal haematopoiesis can be applied to both cancer and to care of COVID patients
The Oxford-led UK Coronavirus Cancer Monitoring Project was launched earlier this year to help clinicians better treat blood cancer patients in a safe way during the COVID-pandemic
Scientists from Tanzania, Uganda and Oxford University have teamed up in a new child blood cancer program
New Nature paper reveals discovery of a genetic vulnerability in nearly 10% of breast cancer tumours and how this can be targeted to selectively kill cancer cells.
Dr Rebecca Shakir is devising a tool to allow some blood cancer patients to make more informed decisions about the risks and benefits of their radiotherapy treatment
Development fund winners Rosalin Cooper & Ben Fairfax are investigating the epigenetic landscape of melanoma patients and how it can impact patient sensitivity to ICB therapy
Prof Paresh Vyas and his team are investigating how to harness the power of T cells as therapies for patients with a range of blood cancers